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Abstract
Botswana was one of the first African countries to transition from WHO Option A to Option B for 
prevention of mother-to-child HIV transmission (MTCT). We evaluated the impact of this 
transition on projected MTCT risk through review of 10,681 obstetric records of HIV-infected 
women delivering at 6 maternity wards. Compared with Option A, women receiving antenatal care 
under Option B were more likely to receive combination antiretroviral therapy (ART), adjusted 
odds ratio (aOR) 2.59 (95% confidence interval [CI] 2.25-2.98), but they were also more likely to 
receive no antenatal antiretrovirals, aOR 2.10 (95% CI 1.74-2.53). Consequently, initial 
implementation of Option B was associated with increased projected MTCT at 6 months of age, 
3.79% under Option A and 4.69% under Option B (P<0.001). Successful implementation of 
Option B or B+ may require that ART can be initiated within antenatal clinics, and novel 
strategies to remove barriers to rapid ART initiation.
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Introduction
Expanded access to maternal combination antiretroviral therapy (ART) has the potential to 
nearly eliminate pediatric HIV infection.1 In 2010, the WHO recommended that one of two 
strategies be adopted for prevention of mother-to-child transmission (PMTCT) for women 
who did not require treatment for their own health (CD4+ cell count >350 cells/μL and 
WHO clinical stage 1 or 2)— Option A, antenatal maternal zidovudine monotherapy, or 
Option B, maternal ART during pregnancy and breastfeeding.2 However, recognizing a 
number of implementation challenges with Option A,3 and observing encouraging results 
from expanded maternal ART in Malawi,4 in 2013 the WHO recommended ART for all 
pregnant and breastfeeding women regardless of CD4 count (Option B), and that ART could 
be continued lifelong (Option B+). Option A was no longer recommended.5
Since 1999, Botswana has had one of the most successful PMTCT programs in Africa. The 
program achieves nearly universal HIV testing in pregnancy, and MTCT of Botswana 
citizens has been reported at less than 5% for nearly a decade.6 To further reduce 
transmission, in 2009 the Botswana government initiated a pilot of Option B in 5 districts 
and this strategy became national policy in 2011.7,8
We sought to evaluate the impact of the programmatic transition from Option A to Option B 
in Botswana on the risk of MTCT. Infant diagnosis is only available for the potentially 
biased subset that survives and presents for testing, so we utilized a large birth surveillance 




Active surveillance was conducted in public maternity wards in all regions of Botswana. 
Surveillance sites were selected to represent diverse settings and included the principal 
maternity wards in Gaborone (surveillance from May 2009 to October 2012), Molepolole, 
Mochudi, Francistown, Maun, and Ghanzi (surveillance from November 2009 to April 
2011). Records for all deliveries occurring after 20 weeks gestation at these maternity wards 
were reviewed.
MTCT Prevention Program
At the time the birth surveillance started, pregnant women with CD4 count ≤ 250 cells/μL 
(or WHO clinical stage 3 or 4) were eligible for ART for their own health. HIV-infected 
women with CD4 count >250 cells/μL received zidovudine (provided by antenatal staff 
onsite) from 28 weeks gestation and single-dose nevirapine in labor.10 Specimens for CD4 
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were drawn at the antenatal clinic and analyzed in central laboratories; women eligible for 
treatment were referred to ART clinics, many offsite.
As part of the Option B pilot in 2009, women with CD4 count > 250 cells/μL were eligible 
to receive ART. When Option B became national policy in 2011, women with CD4 count 
≤350 cells/μL were eligible for ART for life and women with CD4 count >350 cells/μL were 
eligible for ART during pregnancy and breastfeeding. Under these guidelines, ART was 
prescribed at ART clinics (not in antenatal clinics) following receipt of CD4 results and 
completion of adherence counseling. The national rollout of Option B occurred from early 
2011 to early 2012. The birth surveillance included the entirety of two pilot sites and the 
first 12 months of the nationwide implementation of Option B. Throughout the surveillance 
period, replacement feeding was recommended for most women according to government 
guidelines and infant formula provided. Infant prophylaxis beyond single-dose nevirapine 
and 4-weeks of zidovudine was not provided.
The study was reviewed and approved by the Botswana Health Research Development 
Committee and the Institutional Review Board of the Harvard School of Public Health. A 
waiver for the requirement of informed consent was received to review health records.
Projected MTCT Risk
For each delivery record for an HIV-infected mother, an individual projected risk of MTCT 
was calculated conditional on maternal CD4 strata, type of maternal antiretroviral therapy 
received, and infant feeding method following published methodology.11 Infant feeding 
status was defined as the method used while on the maternity ward, and women opting to 
breastfeed were assumed to exclusively breastfeed for 6 months. We used the conditional 
MTCT estimates11 utilized in the base Spectrum model as our primary inputs, and in 
sensitivity analyses used high and low estimates and inputs conditional on duration of ART 
received from published estimates 12-20 (supplemental Table S1).
Statistical Analysis
As rollout of Option B occurred in a staged fashion, in order to compare clinical 
performance under the two PMTCT strategies we defined two exposure groups. Women 
registering for antenatal care at a clinic that had not yet implemented Option B were 
considered in the Option A group. Women registering after their clinic had implemented 
Option B were considered in the Option B group. The date of clinic transition from Option 
A to Option B was defined as the date for the first sustained use in that district of ART for 
women with CD4 count >350 cells/μL. PMTCT interventions actually received were 
determined by data abstracted from medical records. As non-citizens were not eligible for 
the free PMTCT program, only records for Botswana citizens were analyzed to assess 
impact of programmatic change.
We used LOESS regression to describe longitudinal trends. Multivariable linear and logistic 
models were fit to assess the impact of the implementation of Option B on the projected 
MTCT risk and the receipt of maternal antenatal antiretrovirals, respectively. Models 
accounted for clustering effects at the district and clinic level and adjusted for maternal age, 
marital status, employment, education, knowledge of HIV diagnosis prior to pregnancy, 
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delivery hospital, presence of an onsite ART clinic, and antenatal clinic location (urban, 
large village, rural). Statistical analyses were performed with the use of the SAS statistical 
package, version 9.3 (SAS Institute, Cary, North Carolina). All tests were two-tailed and P-
values of less than 0.05 were considered statistically significant.
Results
Surveillance cohort
During the surveillance period at the study maternity wards there were 35,281 live born 
deliveries by Botswana citizens. Of these, 10,681 (29.2%) women were HIV-infected, 
24,600 (69.7%) were HIV-uninfected, and 368 (1.0%) had unknown HIV status. Women 
received antenatal care at 398 different clinics and health posts. Maternal and clinic 
characteristics were similar between women registering during Option A versus Option B 
(Table 1).
Antiretroviral use
The proportion of HIV-infected women recorded as receiving ART at the time of delivery 
more than doubled during the surveillance period. Half of the increase in ART use during 
pregnancy was attributable to an increasing proportion of HIV-infected women already on 
ART at the time of conception. The remaining half of the increase was attributable to the 
shift to Option B for PMTCT, and the resulting increase in ART-eligible women. Following 
the adoption of Option B as national policy, ART initiation during pregnancy increased 
from 20% to 46% (Figure 1a).
The proportion of HIV-infected citizens receiving no antenatal antiretroviral treatment by 
delivery increased during the surveillance period. The increase was temporally correlated 
with the initial pilot and then the national adoption of Option B (when zidovudine was no 
longer regularly prescribed at antenatal clinics). Among ART-naïve women, 11.1% under 
Option A and 16.4% under Option B received no antenatal antiretrovirals.
In adjusted analyses, ART-naïve women registering at a clinic implementing Option B were 
significantly more likely to receive ART during pregnancy compared to women registering 
at an Option A clinic, adjusted odds ratio (aOR) 2.59 (95% confidence interval [CI] 
2.25-2.98, P<0.001). However, they were also significantly more likely to receive no 
antenatal antiretrovirals by the time of delivery, aOR 2.10 (95% CI 1.74-2.53, P<0.001). 
Registration under Option B was also associated with an increased odds of receiving no 
antiretrovirals among the subset of women with CD4 <250 cells/μL, OR 2.58 (95%CI 
1.97-3.38, P<0.001), although these women were eligible for ART throughout the 
surveillance period.
Projected MTCT
During the surveillance period, overall projected MTCT increased (Figure 1b). This 
projected increase was greatest (58%) among women with CD4 <250 cells/μL. In 
multivariable analyses, registering for antenatal care at a clinic implementing Option B was 
associated with an absolute increase of 0.90% in projected MTCT (95% CI 0.62-1.18% 
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increase, P<0.001) compared with Option A. Holding other factors at their population 
means, projected MTCT was 3.79% for women registering under Option A and 4.69% under 
Option B. Using these estimates, nationwide 528 annual infant infections are projected to 
have occurred under Option A and 653 under Option B (increase of 125 annual infections, 
24%, 95% CI 16-31%). Sensitivity analyses varying risk of MTCT and utilizing inputs that 
included gestational age of antiretroviral initiation resulted in similar findings (supplemental 
Table S2).
Registration for antenatal care earlier in pregnancy, older maternal age, diagnosis of HIV 
infection prior to pregnancy, ART at the time of conception, and increased education were 
associated with decreased projected MTCT (supplemental Table S3). Presence of an onsite 
ART clinic (co-located with antenatal clinic but generally with separate staff and record 
systems) was also associated with decreased projected MTCT, but impact was limited. 
Among ART-naïve women under Option B, 28.3% with offsite ART clinics and 33.5% with 
onsite ART clinics successfully started ART (P = 0.011). Under Option A, where 
zidovudine was prescribed and dispensed by antenatal clinic staff, 89.1% received 
antiretrovirals.
Discussion
In this observational study under operational conditions in Botswana, the initial phase of 
programmatic Option B rollout was associated with a 24% increase in projected MTCT, 
from 3.79% to 4.69%. While antenatal ART use increased sharply with implementation of 
Option B, rates of women receiving no antiretroviral therapy unfortunately also increased, 
offsetting the gains resulting from expanded access to ART. To our knowledge, this is the 
first study to investigate the programmatic transition from a well-implemented Option A 
strategy to Option B.
Discussions with patients, midwives, ART clinicians, and program officers offer several 
possible explanations for unexpected poor coverage during Option B implementation. Under 
Option A, the antenatal clinic midwife managed the entirety of the pregnancy, including 
PMTCT. Women with low CD4 cell counts were referred to ART clinics to initiate ART, 
but started zidovudine at 28 weeks gestation while awaiting ART. Consequently, women 
unable to access ART prior to delivery did receive zidovudine. Under Option B, all HIV-
infected women were referred to ART clinics and antenatal clinics no longer prioritized 
dispensing zidovudine. Women referred to the ART clinics, and the lay counselors who 
aided them, reported encountering barriers to ART initiation that included lack of 
transportation, repeat laboratory testing, and perceived requirements for adherence 
counseling and an adherence partner. Additionally, clinicians reported that more women 
were reluctant to accept ART than zidovudine alone.
The surveillance period only captures the first 12 months of national implementation of 
Option B. The surveillance does not reflect current program performance following actions 
by the program to address encountered challenges. Preliminary findings from ongoing 
surveillance studies [Botswana-Harvard AIDS Institute Partnership, unpublished data, 2014] 
and aggregate government reports21 indicate subsequent improvement. However, these data 
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from the first year in Botswana may reflect the challenges of many programs beginning to 
make the transition from Option A to Option B now, and so it is critical to understand the 
initial period of rollout.
There are a number of limitations that should be considered when interpreting the results of 
this study. We utilized projected MTCT risk rather than observed infant infections. While 
the projections were based on observed risks in high quality studies, it is uncertain how 
accurately they reflect actual transmission. Analyses are based on antiretroviral use as 
documented in the record. In this and prior work we have not observed frequent 
discrepancies, but cannot exclude the possibility of bias.
In conclusion, initial implementation in Botswana of WHO Option B was associated with a 
24% increase in projected MTCT due to increased proportion of women receiving no 
antenatal antiretrovirals. Options B and B+ have many advantages for PMTCT delivery. 
However, successful implementation may require removal of barriers to rapid ART 
initiation (such as by integrating ART into antenatal clinics), and support for early 
engagement in antenatal care. Programs may also benefit from introducing novel strategies 
to improve acceptance of timely ART by pregnant women. Botswana is now supporting 
initiation of ART within antenatal clinics and ART initiation prior to receipt of CD4 results, 
and these are important steps towards eliminating MTCT.
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Figure 1. Antiretroviral use and projected mother-to-child transmission, LOESS regression
Trends in antiretroviral use among HIV-infected pregnant women during the surveillance 
period, demonstrating increases both in the proportion of women receiving combination 
ART and no antenatal antiretrovirals, Panel A. Corresponding increases in projected MTCT 
during in the initial implementation of Option B as demonstrated by solid line (Spectrum 
base inputs) and dotted lines (high and low Spectrum inputs), Panel B. Projected MTCT 
adjusted for delivery site.
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Age at delivery (years), median (quartiles) 29.0 (25.0, 33.0) 29.0 (25.0, 33.0)
Secondary school education, no. (%) 5280 (83.1) 2790 (81.7)
Employed in formal sector, no. (%) 3330 (55.2) 1669 (60.7)
Nulliparous, no. (%) 3060 (49.6) 1086 (45.8)
Gestation age at ANC registration, median (quartiles) 19.6 (15.4, 24.3) 20.4 (16.0, 25.3)
HIV diagnosed before current pregnancy, no. (%) 3152 (46.9) 1814 (50.7)
Recent CD4+ cell count (cells/μL), median (quartiles) 381 (251, 529) 398 (264, 554)
No recorded CD4 results, no. (%) 3308 (49.2) 1802 (50.3)
HAART prior to conception, no (%) 1760 (26.2) 1008 (28.2)
Dates of LNMP not available, no. (%) 175 (2.6) 181 (5.1)
Breastfed infant at maternity, no. (%) 509 (7.6) 381 (10.7)
Antenatal Clinic Characteristics
Clinic location, no. (%)
 Urban (population >50,000) 4375 (67.8) 1810 (51.6)
 Large village (population 20,000-50,000) 634 (10.8) 364 (10.4)
 Rural (population <20,000) 1384 (21.5) 1332 (38.0)
Delivery hospital, no. (%)
 Princess Marina Hospital, Gaborone 2753 (40.9) 1983 (55.4)
 Scottish Livingston Hospital, Molepolole 280 (4.2) 732 (20.4)
 Deborah Retief Memorial Hospital, Mochudi 758 (11.3) 28 (0.8)
 Nyangabgwe Referral Hospital, Francistown 1714 (25.5) 510 (14.2)
 Letsholathebe Memorial Hospital, Maun 1205 (17.9) 39 (1.1)
 Ghanzi Memorial Hospital, Ghanzi 21 (0.3) 290 (8.1)
Pregnancy potentially affected by strike, no. (%) a 783 (11.6) 487 (13.6)
Onsite ART clinic at antenatal clinic, no. (%) 3272 (48.7) 2393 (68.1)
Note. ANC, antenatal clinic; LNMP, last normal menstrual period
a
Pregnancies in their second or third trimester during the period of the general public service strike (April to June 2011) that affected operation at 
most antenatal clinics.
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